Last updated: February 19, 2026
Cisatracurium besylate is a neuromuscular blocking agent used primarily during anesthesia procedures. Its global supply chain involves multiple manufacturers, both branded and generic.
Major Suppliers and Manufacturers
| Company |
Location |
Market Role |
Notable Approvals |
| Pfizer |
United States |
Patent holder, branded product |
Tradename: Nimbex |
| Hospira (Pfizer subsidiary) |
United States |
Generic producer |
FDA-approved biosimilar versions |
| Fresenius Kabi |
Germany / Global |
Generic manufacturer |
Approved in Europe, Asia |
| Sandoz (Novartis) |
Switzerland / Global |
Generic producer |
Approved in U.S., Europe |
| Hikma Pharmaceuticals |
United Kingdom |
Generic provider |
Approved in Middle East, Europe |
| Jiangsu Hengrui Medicine Co., Ltd. |
China |
Generic manufacturer |
Approved in China, some other markets |
Supply Chain Considerations
- Patent Status: Pfizer held the original patent. As of 2014, patents expired in many regions, leading to increased generic production.
- Regulatory Approvals: Manufacturers must secure approval from agencies like the FDA, EMA, or equivalent authorities in their markets.
- Manufacturing Capacity: US-based firms (Pfizer, Hospira) dominate high-volume markets. Asian producers (Jiangsu Hengrui) serve regional markets and are expanding globally.
- Pricing Trends: Generic suppliers have driven prices down; Pfizer’s branded Nimbex remains a premium product mainly for specific markets or institutional contracts.
Regulatory and Market Dynamics
- US Market: Dominated by Pfizer’s Nimbex, with generics by Hospira and other suppliers. Approval pathways for generics are streamlined under the Abbreviated New Drug Application (ANDA) process.
- European Market: Several manufacturers, including Fresenius Kabi and Sandoz, offer approved alternatives.
- Emerging Markets: Greater reliance on regional generics, often with local manufacturing sites.
Critical Supply Factors
- Quality Control: Suppliers must maintain rigorous standards due to the drug’s parenteral administration.
- Supply Chain Disruptions: Global logistics, regulatory delays, or manufacturing issues can impact availability.
- Market Entry Barriers: Regulatory approval, scale, and pricing influence new entrants.
Summary
The principal suppliers of cisatracurium besylate are Pfizer (branded Nimbex), Hospira (generic), Fresenius Kabi, Sandoz, and Hikma. These firms collectively serve major markets, with regional players emerging in Asia and other territories.
Key Takeaways
- Patent expiration has increased the number of generic suppliers.
- Pfizer remains the primary branded manufacturer, especially in the U.S.
- Market distribution varies regionally, influenced by regulatory approvals.
- Supply stability depends on quality control, regulatory compliance, and geopolitical factors.
FAQs
1. Who is the primary supplier of branded cisatracurium besylate?
Pfizer markets the branded form under the name Nimbex.
2. Are generic versions widely available?
Yes, multiple manufacturers such as Hospira, Fresenius Kabi, and Sandoz supply generic cisatracurium besylate.
3. What regions have the most suppliers?
The U.S. and Europe have numerous approved suppliers; Asian manufacturers are expanding presence globally.
4. How do regulatory approvals impact supply?
Approval delays or restrictions can limit market availability, especially for new entrants and generics.
5. What risks exist for supply chain disruptions?
Manufacturing problems, supply chain logistics, and regulatory issues can cause shortages or delays.
References
[1] U.S. Food and Drug Administration. (2022). Abbreviated New Drug Application (ANDA) approvals.
[2] European Medicines Agency. (2022). Summary of Product Characteristics for cisatracurium.
[3] GlobalData. (2022). Market analysis of neuromuscular-blocking agents.
[4] Pfizer Inc. (2022). Product information for Nimbex.
[5] Sandoz International GmbH. (2022). Product approvals and manufacturing standards.
